Compare FISI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISI | ABUS |
|---|---|---|
| Founded | 1817 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.7M | 836.0M |
| IPO Year | 1999 | 2008 |
| Metric | FISI | ABUS |
|---|---|---|
| Price | $40.44 | $4.06 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | 92.0K | ★ 2.7M |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | ★ 231.27 | 55.26 |
| EPS | ★ 2.08 | 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $6.23 | $1,208.75 |
| Revenue Next Year | $4.91 | N/A |
| P/E Ratio | $18.88 | ★ $4.61 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $28.21 | $3.50 |
| 52 Week High | $42.97 | $5.45 |
| Indicator | FISI | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 29.13 |
| Support Level | $37.87 | $3.50 |
| Resistance Level | $40.33 | $4.57 |
| Average True Range (ATR) | 0.83 | 0.15 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 34.27 | 1.96 |
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.